Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
TG Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Prior treatment in clinical trial UTX-TGR-304
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
You may not be if
Participants refractory to ublituximab + TGR-1202
Transformation of chronic lymphocytic leukemia (CLL) to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Clareo Health | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
